CureSign
Monitoring Cancer Treatment Efficacy
StartupCureSign is a Magshimim-based startup in the Health Tech & Life Sciences sector, established in 2019. Monitoring Cancer Treatment Efficacy. CureSign was founded by Yakir Rottenberg. Key investors include Peregrine Ventures, Nacre Capital. The company has 1-10 employees. Core technologies: Sensing, Artificial Intelligence.
The company follows a B2B business model. Product stage: R&D.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQMagshimim
- DistrictCenter District
- Last RoundUndisclosed
- Peregrine Ventures
- Nacre Capital
Yakir RottenbergCo-founder, Inventor & Medical Director
What does CureSign do?
Curesign is a medical device company aiming to disrupt the way oncologists treat patients with cancer. The companys solution is based on the integration of sensors with advanced signal-processing and big data tools. Curesigns product, which is in the advanced stages of development, is designed to allow clinical teams to tailor a patient-specific treatment for each cancer patient. Curesigns technology has been successfully demonstrated in preclinical studies. Based on the results, the company is currently working on a commercial product for use in many preclinical trials in the field of oncology.
Who founded CureSign?
CureSign was founded in 2019 by Yakir Rottenberg (Co-founder, Inventor & Medical Director).
What sector is CureSign in?
CureSign operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, Digital Healthcare, Medical Decision Support, with core technologies in Sensing, Artificial Intelligence. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is CureSign located?
CureSign is based in Magshimim, Israel, Center District.